Chemical inhibitors of A230107C01Rik function by engaging with specific signaling pathways and enzymes that are crucial for the protein's activity. Staurosporine, for example, is known to inhibit protein kinases broadly, which can lead to the inhibition of A230107C01Rik by blocking the phosphorylation processes that are necessary for its activation within kinase signaling cascades. Similarly, Bisindolylmaleimide I targets Protein Kinase C (PKC), which is integral in the signaling pathways that regulate A230107C01Rik's function. By inhibiting PKC, Bisindolylmaleimide I can reduce the activity of A230107C01Rik. H-89, another kinase inhibitor, focuses on Protein Kinase A (PKA) and is capable of diminishing the phosphorylation and subsequent activation of A230107C01Rik or its associated proteins.
Further along these lines, U73122 functions by inhibiting phospholipase C (PLC), a pivotal player in the signaling mechanisms that activate A230107C01Rik. By preventing PLC activity, U73122 effectively hampers A230107C01Rik function. LY294002 operates through the inhibition of phosphoinositide 3-kinases (PI3K), which participate in regulating A230107C01Rik. PD98059 and SB203580 target the MAPK pathway at different points; PD98059 inhibits MEK, which is upstream of ERK and can regulate A230107C01Rik, while SB203580 specifically inhibits p38 MAPK, another kinase that impacts A230107C01Rik's signaling. SP600125's inhibition of c-Jun N-terminal kinase (JNK) also attenuates signaling pathways relevant for A230107C01Rik activity, leading to its functional inhibition. PP2 selectively inhibits Src family tyrosine kinases, which affect the regulation of A230107C01Rik, and Dasatinib provides broad-spectrum inhibition of tyrosine kinases like Bcr-Abl and Src family kinases, which are involved in the regulatory pathways of A230107C01Rik. Lapatinib's inhibition of the epidermal growth factor receptor (EGFR) and HER2, as well as Sorafenib's targeting of multiple receptor tyrosine kinases, disrupts signaling cascades that are crucial for A230107C01Rik's regulation and activity, thereby leading to functional inhibition of the protein.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits protein kinases, which can lead to the inhibition of A230107C01Rik by preventing its phosphorylation and activation that is dependent on kinase signaling cascades. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of Protein Kinase C (PKC) which is involved in the signaling pathways that regulate the activity of A230107C01Rik, thus its inhibition can hinder A230107C01Rik function. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
H-89 is a potent inhibitor of Protein Kinase A (PKA), and by inhibiting PKA, it can reduce the phosphorylation of A230107C01Rik or its associated proteins, leading to the functional inhibition of A230107C01Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of phosphoinositide 3-kinases (PI3K), which are involved in the signaling pathways that regulate A230107C01Rik, leading to its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinase (ERK) that could regulate A230107C01Rik, thus inhibiting A230107C01Rik function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor; by inhibiting p38 MAPK, it can decrease the signaling that regulates the function of A230107C01Rik, resulting in its inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in signaling pathways that regulate A230107C01Rik activity, thus its inhibition leads to the inhibition of A230107C01Rik. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases, which could be involved in signaling pathways that regulate A230107C01Rik, and its inhibition can lead to the functional inhibition of A230107C01Rik. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor that targets Bcr-Abl and Src family kinases which are potentially involved in the regulation of A230107C01Rik, leading to its inhibition. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib inhibits the epidermal growth factor receptor (EGFR) and HER2, which are part of the pathways that regulate the activity of A230107C01Rik, leading to its functional inhibition. | ||||||